Abstract. Esophageal squamous cell carcinoma (SCC) is one of the biological malignant tumors. Once a tumor invades the submucosa, an incidence of lymph node (LN) metastases is very high, thus resulting in poor survival. Recently, chemokines have been reported to play an important role in organ-specific metastases in several malignancies. In particular, CCR7 has been reported to be associated with LN metastases by immunohistochemistry. However, there have been no studies of quantitative analyses of CCR7 mRNA expression on cancer cells. In this study, we investigated the clinical significance of the expression of CCR7 in the establishment of LN metastases of esophageal SCC. A series of 78 patients with esophageal SCC who underwent esophagectomy were consecutively selected. The expression of CCR7 mRNA from tumor tissue samples was analyzed by quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR), and that from cancer cell samples collected using laser microdissection system was analyzed by qRT-PCR. Immunohistochemical staining of CCR7 was also performed. Although CCR7 mRNA expression in tumor tissues demonstrated no association with the LN metastases, that in cancer cells correlated with LN metastases (p<0.05) due to the fact that not only cancer cells but also infiltrating lymphocytes expressed CCR7 in tumor tissue. Multivariate logistic regression analysis revealed a high CCR7 expression in cancer cells to be an independent predictive factor for LN metastases. These results suggested that CCR7 expression might play an important role in establishing LN metastases in patients with esophageal SCC.

Introduction

Esophageal squamous cell carcinomas (SCCs) are malignant, once the tumors invade the sub-mucosa, 8.3-28.6% have lymph node involvements and in ~34.8-54.1% deeper invasion to submucosa causes lymph node metastases, resulting in poor survival (1-6).

Chemokines have previously been reported to play an important role in both tumor growth and in establishing organ-specific metastases in several malignancies (7-19). The expression of CXCR4 in gastric cancer correlates with peritoneal dissemination (9) and cancerous CXCL12 expression was an independent prognostic factor in gastric cancer (10) and the expression of CCR6 in colorectal cancer is associated with synchronous liver metastases (11). CCR7 is concerned with the homing of lymphocytes to secondary lymphoid organs. Müller et al have reported the expression of the ligands of chemokines in the organs to be associated with the formation of metastases and the CCR7/CCL21 axis has also been shown to play an important role in lymph node metastases in breast cancer (12). Since then, several studies have also reported the CCR7 expression to be associated with lymph node metastases in malignant melanoma (13,14), breast carcinoma (15), non-small cell lung carcinoma (16) and gastrointestinal carcinomas (17). In gastric cancer, the CCR7 expression has a significant correlation with lymph node metastasis and lymphatic invasion by immunohistochemical analysis (18). In esophageal SCC, a high expression of CCR7 is associated with lymph node metastasis, TNM-stage and depth of tumors, resulting in poor survival in immunohistochemical study (19).

However, there have been no studies of quantitative analyses of CCR7 mRNA expression on cancer cells. Whole tumor tissue contains not only cancer cells but also many infiltrating lymphocytes which express CCR7. Therefore, it is important to exclude infiltrating lymphocytes when we quantitatively analyze CCR7 expression in tumor tissue.

In this study, we quantitatively investigated the expression of CCR7 mRNA in cancer cells using laser microdissection in patients with esophageal SCC, and we assessed the association of CCR7 expression with lymph node metastases to clarify the role of the CCR7 in cancer...
cells in the establishment of lymph node metastases in patients with esophageal SCC.

Materials and methods

Patient selection and tissue specimens. A series of 78 patients with esophageal SCC who underwent esophagectomies at Wakayama Medical University Hospital between April 2003 and February 2006 were consecutively selected. Most of the patients had undergone an esophagectomy with lymph node dissection through a right thoracotomy. None of them received either chemotherapy or radiotherapy before surgery. Clinico-pathological characteristics of these 78 patients are shown in Table I. The tumor specimens were divided into two parts. One was immediately frozen in liquid nitrogen after surgical resection and stored at -80°C until RNA extraction, and the other was fixed in a 10% formaldehyde solution and embedded in paraffin for immunohistochemical analysis and for common histological diagnosis. The primary tumors of the esophagus were histologically examined with hematoxylin and eosin staining according to TNM classification of malignant tumors by UICC (20).

Forty-three tissue samples, out of 78 patients, were large enough for sampling by laser microdissection (LMD) and were analyzed for quantitative real-time RT-PCR. In addition, the 78 tissue samples were analyzed immunohistochemically.

Written informed consent was obtained from all patients before their participation in this study. In addition, the local Ethics Committee of Wakayama Medical University approved this study.

Laser microdissection. For LMD, each tissue block was cut off from 43 specimens and embedded in the Tissue Tek OCT medium (Sakura, Tokyo, Japan) and frozen in liquid nitrogen for 30 min. The frozen tissue blocks were sliced in 6-8 μm by Cryostat (Sakura) and mounted on foil-coated glass slide (FOIL-SL25; Leica Microsystems). Before LMD, the sections were fixed with 70% ethanol for 1 min at -20°C and after washing in ethanol, they were stained with hematoxylin for 1 min. After being air dried, the cancer cells of the sections were selectively microdissected using the Leica LMD System (Leica Microsystems, Wetzlar, Germany) (21-23).

RNA extraction and complementary DNA synthesis. Total RNA was extracted from tumor tissue specimens using RNeasy mini kit (Qiagen, Hilden, Germany) and as well as from microdissected cancer cells using RNeasy micro kit (Qiagen). The quality of RNA was assessed by 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) for quantitative RT-PCR.

Complementary DNA (cDNA) was generated with the transcriptor first-strand cDNA synthesis kit (Roche Diagnostics, Mannheim, Germany). The total RNA (1 μg) was denatured in a 13 μl solution for 10 min at 65°C. The cDNA synthesis reaction was performed at 55°C for 30 min and heated at 85°C for 5 min for inactivation.

Quantitative real-time RT-PCR. Quantitative real-time RT-PCR (quantitative RT-PCR) was performed with the isolated total RNA (1 μg) on LightCycler system (Roche, Germany). The following oligonucleotide primers and hybridization probes were used: human CCR7 (Gene Bank accession no. NM_001838; 969-1199 bp) sense (5'-GCAACTCAACACTCG CCTACG-3') and antisense (5'-TATGGGGAGAAGGT GGTTGGT-3'), Fluorescein-labeled probe (5'-ACCTTTCTT GTACGCCCTCACCTGG-3'), and LC Red 640-labeled probe (5'-GTCAAGTTCCGCAACGATCTCTTCAAG-3'), human GAPDH (Gene Bank accession no. NM_002046; 746-1052 bp) sense (5'-TGAACGGGAAGCTCACTGG-3'), human GAPDH (Gene Bank accession no. NM_002046; 746-1052 bp) sense (5'-TGAACGGGAAGCTCACTGG-3'), and antisense (5'-TCCACACACTCTTGGCTGTA-3'), Fluorescence-labeled probe (5'-TCAACAGGCAACACCCACTCCT-3') and LC Red 640-labeled probe (5'-CACCTTTGACGCTGGG GCT-3'). All primers and probes were designed and synthesized at the Nihon Gene Research Laboratory, Inc.

CCR7 cDNA was amplified by 50 cycles of denaturation at 95°C (10 sec), annealing at 60°C (10 sec) and extension at 72°C (12 sec). GAPDH cDNA was amplified by 55 cycles of denaturation at 95°C (10 sec), annealing at 55°C (15 sec) and extension at 72°C (9 sec).

On each run, we quantified all samples according to the LightCycler software program ver. 3.8. The values of CCR7 were standardized by the values of GAPDH in all samples.

Since it was assumed that the CCR7 expression demonstrated a logarithmic normal distribution, we used the following for quantitative RT-PCR analysis: CCR7 ratio = log (CCR7 value/GAPDH value *10^4).

Immunohistochemistry. Immunohistochemical staining was performed by the polymer envision method. For the double
staining method, two antibodies were used: anti-h CCR7 (Epitomics, Inc, CA, USA) and anti-h Leucocyte Common Antigen (LCA) (DakoCytomation, Denmark). The 5-μm tissue sections were heated at 121˚C in an autoclave for 7 min after deparaffinization and rehydration. Exogenous peroxidase activity was suppressed by a solution of 0.3% hydrogen peroxide in methanol for 5 min. After being rinsed in Tris-TBS, the sections were incubated with a blocking reagent: Protein block (Dako, Kyoto, Japan) for 20 min at room temperature. The sections were then incubated overnight at 4˚C with the first antibody. After rinsing, the sections were incubated for 90 min with the second antibody: Histofine Simple Stain (Nichirei, Tokyo, Japan). Color reaction was developed in AEC solution (DakoCytomation). After the first reaction was inactivated with 0.1 M glycine buffer (pH 2.2), the sections were then incubated overnight at 4˚C with the next antibody. After rinsing, they were incubated for 60 min with the next antibody: namely, anti-mouse or rabbit Ig/AP (Dako Cytomation) and then after rinsing, they were reacted with Vector Blue (Vector Laboratories, Inc, USA).

The primary cancer tissue specimens were double stained with CCR7 and LCA and the sections were regarded as CCR7-positive when the intensity of staining was >10%.

Statistical analysis. Comparisons between the CCR7 ratio and the clinicopathological features were performed using either Student's t-test or ANOVA as appropriate. The diagnostic accuracy of CCR7 expression with regard to the presence of lymph node metastases was quantified via a receiver operating characteristic (ROC) analysis (24,25). The associations between CCR7 expression and clinicopathological features were evaluated by either the χ² test or Fisher's exact test as appropriate. Univariate and multivariate logistic regression analyses were carried out to investigate whether the presence of CCR7 expression would be an independent risk factor for lymph node metastases. All analyses were performed using the Stat View-J ver.5.0 software program and all tests were two-sided with a significance level of p<0.05.

Results

Correlation between CCR7 mRNA expression in tumor tissues and lymph node metastases or lymphatic invasion. We first examined the mRNA expression of CCR7 in whole tumor tissue specimens. The expression of CCR7 mRNA in tumor tissue specimens was not significantly associated with either lymph node involvement or with lymphatic invasion (Fig. 1A).

Immunohistochemistry for CCR7 in tumor tissues. Immunohistochemistry for CCR7 was performed to examine where CCR7 was expressed in the tumor tissue specimens. CCR7 was expressed in the cytoplasm and cell membrane of cancer cells (Fig. 2A-C). In most samples, CCR7 was expressed heterogeneously (Fig. 2C). On the other hand, CCR7 was constantly expressed in normal lymphocytes. Expression level of CCR7 was usually higher in normal lymphocytes than in cancer cells (Fig. 2A-E). Therefore, the expression of CCR7 mRNA in tumor tissues was derived from both cancer cells and infiltrating lymphocytes.
Correlation between CCR7 mRNA expression in cancer cells themselves and lymph node metastases. To investigate the expression of CCR7 mRNA in the cancer cells, we selectively microdissected cancer cells using the LMD system and extracted total RNA from cancer cells in 43 tumor tissues (Fig. 3). We analyzed the quality of the extracted RNA by using 2100 Bioanalyzer, the extracted RNA in 10 of 43 cases was found to be damaged and therefore it was excluded from the subsequent RT-PCR. The expression of CCR7 mRNA in cancer cells in cases with lymph node metastasis was higher than that in cases without lymph node metastasis (p<0.05). Other clinicopathological factors were also compared between the cases with lymph node metastases and without lymph node metastases. A significant difference in the expression of CCR7 mRNA was observed in the presence of lymphatic invasion (p<0.05) (Fig. 1B), but no such difference was seen in either the presence of vessel invasion or in any other factors (data not shown).

Twenty-two of the 33 cases were assessed for the level of CCR7 mRNA both in tumor tissue specimens and cancer cells. As expected, these groups had a low correlation (R=0.443, p<0.05) (Fig. 1C).

Figure 2. CCR7 expression in representative esophageal SCC specimens was assessed by immunohistochemistry. Original magnification, x40. (A) Both CCR7 and LCA were stained in the tumor tissue specimens (outline arrows show lymphocytes). (B) H&E staining of the specimens, which is similar to A. (C) CCR7 was expressed heterogeneously in the tumor tissue specimens. (D) Both CCR7 and LCA were stained in lymphocytes (outline arrows). (E) H&E staining of the specimen, which is similar to D.
Figure 3. (A) Hematoxylin staining of the specimen. Original magnification, x100. (B and C) Cancer cells stained by hematoxylin were selectively cultured by using the Leica Laser Microdissection system, which is similar to A.

Table II. Comparison of the clinicopathological characteristics with the CCR7 expression.

<table>
<thead>
<tr>
<th>Clinical factor</th>
<th>CCR7 expression</th>
<th>Comparison of high vs. low group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low (n=18)</td>
<td>High (n=15)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female/Male</td>
<td>2/16</td>
<td>4/11</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65 years/&gt;65 years</td>
<td>7/11</td>
<td>8/7</td>
</tr>
<tr>
<td>Depth of tumor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1,T2/T3,T4</td>
<td>1/17</td>
<td>3/12</td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wel/Mod/Por</td>
<td>5/10/3</td>
<td>7/4/4</td>
</tr>
<tr>
<td>Lymphatic invasion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative/Positive</td>
<td>11/7</td>
<td>4/11</td>
</tr>
<tr>
<td>Vascular invasion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative/Positive</td>
<td>6/12</td>
<td>7/8</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative/Positive</td>
<td>10/8</td>
<td>2/13</td>
</tr>
<tr>
<td>Number of the metastatic LNs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-3/4-7/8-</td>
<td>14/1/3</td>
<td>9/4/2</td>
</tr>
<tr>
<td>TNM N and M</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0/N1/M1a/M1b</td>
<td>10/4/1/3</td>
<td>2/5/5/3</td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I, IIA/IIB, III/IVA, IVB</td>
<td>10/4 /4</td>
<td>3/4/8</td>
</tr>
</tbody>
</table>

Wel, well differentiated; Mod, moderately differentiated and Por, poorly differentiated. <sup>a</sup>χ² test; <sup>b</sup>Fisher's exact test and <sup>c</sup>P<0.05.
Comparison of clinicopathological characteristics with CCR7 expression of cancer cells. The optimal cutoff level of CCR7 mRNA expression for differentiation between positive and negative lymph node metastases was set at 1.275 by constructing a ROC curve. The sensitivity, the specificity and the accuracy of this cutoff line was 61.9, 83.3 and 69.7%, respectively. Patients were dichotomized as having either a high or low CCR7 expression based on this cutoff level. In addition, the clinicopathological characteristics of the patients were assessed with respect to high vs. low CCR7 expression.

Correlation of CCR7 expression of cancer cells and the presence of lymph node metastases. The patients were grouped according to the presence of lymph node metastases and both univariate analysis and multivariate logistic regression analysis were carried out to identify any independent risk factors for lymph node metastases.

Thirty-eight of the 78 patients had lymph node metastasis. Univariate analyses revealed an association between a CCR7 mRNA high expression, as well as lymphatic invasion and lymph node metastasis (p<0.05).

A multivariate logistic regression analysis, with the presence of lymph node metastases as the dependent variable and all other clinicopathological parameters as independent variables, confirmed the presence of lymph node metastases only to be associated with the expression of CCR7 mRNA (odds ratio: 159.498, p<0.05) (Table III).

Discussion

CCR7 is a chemokine receptor, which is expressed on lymphocytes, such as T cells and dendritic cells and it plays an important role in the mediation of migration of those cells toward lymph nodes which express the CCR7 ligand, CCL21 (26).

CCR7 expression in tumor tissue specimens has recently been reported to be associated with lymph node metastases by immunohistochemical analyses in various carcinomas.
(12-19). However, there are no studies to investigate this correlation quantitatively, although the chemokine-chemokine receptor interaction is targeted in terms of chemotaxis of cancer cells. In this study, we quantitatively examined CCR7 expression of cancer cells by evaluating the mRNA expression, because we thought that the quantity of a chemokine and its receptor were crucial for establishing chemotactic metastases. When we evaluated the mRNA expression level of CCR7 in tumor tissue specimens, the following critical issue remains: A large number of lymphocytes sometimes infiltrate into tumor tissues, suggesting that tumor tissue specimens contain not only cancer cells, but also tumor-infiltrating lymphocytes.

Moreover, our results showed that CCR7 mRNA expression in cancer cells was heterogeneous and extremely low in comparison to that in lymphocytes by immunohistochemistry, and, of course, no correlation was recognized between its expression in tumor tissues and that in cancer cells. Therefore, the evaluation of CCR7 mRNA of whole tumor tissue specimens may not be an accurate indicator for assessing lymph node metastases, and we selectively microdissected cancer cells by using the LMD system to elucidate the CCR7 mRNA expression level in cancer cells themselves in the present study. The results showed the CCR7 mRNA expression of cancer cells in patients with lymph node involvement to be significantly higher than that in patients without lymph node involvement.

Furthermore, when the patients were identified to have a high or low CCR7 expression in cancer cells based on the cutoff level set by constructing a ROC curve, a high CCR7 expression was found to be a significant independent risk factor for lymph node involvement based on a multivariate logistic regression analysis. These findings strongly suggested that CCR7 expressed in cancer cells might play a crucial role in the establishment of lymph node metastases.

CCL21, which is the ligand of CCR7, has been reported to be a key stimulator of cancer cells to migrate into the lymphatic systems (27,28). Lymphatic endothelial cells (LEC) release CCL21, that stimulates malignant melanoma cells to cause directional migration in vitro and melanoma in vivo shows directional growth towards LEC, suggesting that cancer cells recognize and respond to signal given off by the LEC (29). Taken together, cancer cells expressing high level of CCR7 home in on the lymphatics by releasing CCL21 and migrate to lymph node, establishing lymph node metastases.

In conclusion, the high expression of CCR7 mRNA in the cancer cells was clearly associated with lymph node metastases and it was also considered to be an independent predictive factor for lymph node metastases. Therefore, the expression of CCR7 may play an important role in establishing lymph node metastases in patients with esophageal SCC.

References


